Drug Profile
Mesenchymal stem cell therapies - Stempeutics
Alternative Names: ex-vivo cultured adult human mesenchymal stem cells - Stempeutics; ex vivo cultured adult allogenic mesenchymal stem cells - Stempeutics; ex-vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells - Stempeutics; Stempeucel; stempeucel AMI™; stempeucel CLI™; stempeucel COPD™; stempeucel CS™; stempeucel DCM™; stempeucel DM™; stempeucel LC™; stempeucel OA™Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Stempeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Osteoarthritis; Peripheral ischaemia
Highest Development Phases
- Registered Chronic limb-threatening ischemia; Osteoarthritis
- Phase III Diabetic foot ulcer
- Phase I Rectal fistula
- No development reported Chronic obstructive pulmonary disease; Dilated cardiomyopathy; Liver cirrhosis; Myocardial infarction; Stroke; Type 2 diabetes mellitus
Most Recent Events
- 23 Aug 2023 Efficacy data from a phase III trial in Osteoarthritis released by Stempeutics
- 19 May 2023 NCT05854615 - Trial not added as its a phase IV trial
- 27 Sep 2022 Mesenchymal stem cell therapies is still in phase III trials for Diabetic foot ulcer in India (CTRI2019-12-022351) (Stempeutics pipeline, September 2022)